Article Text
Abstract
Background GlcNAc2-epimerase (GNE) myopathy is a rare autosomal recessive disorder caused by pathogenic variants in the GNE gene, which is essential for the sialic acid biosynthesis pathway.
Objective This multi-centre study aimed to delineate the clinical phenotype and GNE variant spectrum in Chinese patients, enhancing our understanding of the genetic diversity and clinical manifestation across different populations.
Methods We retrospectively analysed GNE variants from 113 patients, integrating these data with external GNE variants from online databases for a global perspective, examining their consequences, distribution, ethnicity and severity.
Results This study revealed 97 distinct GNE variants, including 35 (36.08%) novel variants. Two more patients with deep intronic variant c.862+870C>T were identified, while whole genome sequencing (WGS) uncovered another two novel intronic variants: c.52-8924G>T and c.1505-12G>A. Nanopore long reads sequencing (LRS) and further PCR analysis verified a 639 bp insertion at chr9:36249241. Missense variants predominantly located in the epimerase/kinase domain coding region, indicating the impairment of catalytic function as a key pathogenic consequence. Comparative studies with Japanese, Korean and Jewish, our cohorts showed later onset ages by 2 years. The high allele frequency of the non-catalytic GNE variant, c.620A>T, might underlie the milder phenotype of Chinese patients.
Conclusions Comprehensive techniques such as WGS and Nanopore LRS warrants the identifying of GNE variants. Patients with the non-catalytic GNE variant, c.620A>T, had a milder disease progression and later wheelchair use.
- neuromuscular diseases
- genotype
- genetic variation
Data availability statement
Data are available on reasonable request. The original contributions presented in the study are included in the article/online supplemental material. Further inquiries can be directed to the corresponding authors.
Statistics from Altmetric.com
Data availability statement
Data are available on reasonable request. The original contributions presented in the study are included in the article/online supplemental material. Further inquiries can be directed to the corresponding authors.
Footnotes
X @Sushan Luo
KJ, JZ, QL and XLv contributed equally.
Contributors KJ and JZ drafted the manuscript and analysed the data. QL and Xlu designed and carried out LRS and RP-PCR, and analysed data. DH supervised the molecular analysis and created the figures. QK provided technical support for electrophysiological diagnosis. DY analysed muscle imaging and provided technical assistance for muscle pathology. MG provided technical assistance for muscle pathology. CZ verified and interpreted the clinical, pathological and molecular results. JD, ZZ, JS, FQ, XLv, XZ, XChang, LW, ML, BB, HJ, LCL, YL, DY, XC, NW, XX, NC, TW, S-SL, JX, JL, JHL, HZ, YY, BZ, PL, YZ and HY contributed to case diagnosis and acquisition of clinical data. WZ revised the manuscript and supervised the project. JX drafted and revised the manuscript, and designed and supervised the project. ZW designed and conceptualised the study, revised the manuscript and supervised the project. All authors have participated sufficiently in the work and approved the final version of the manuscript for submission. Guarantor for the study: WZ.
Funding WZ and JX were supported by Clinical Research Project Supported by Huashan Hospital, Fudan University; National Natural Science Foundation of China (82171398, 82271437) and Fudan University Brain Science Interdisciplinary Integration Exploration Project (YN-013).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.